Search our library
A lesson learned from COVID-19: The importance of non-inferiority (NI) trials for developing new antimicrobial agents before widespread need
Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?
Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B
Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)